// App-Quantinova.ai

7006 : Effect of olutasidenib (FT-2102) on complete remissions in patients with relapsed/refractory (R/R) mIDH1 acute myeloid leukemia (AML): Results from a planned interim analysis of a phase 2 clinical trial.

Researchers

Presenter

  • Stphane De Botton

Principal Investigators

  • Christian Recher

  • Andrew Wei

  • Pau Montesinos

  • David Taussig

  • Arnaud Pigneux

  • Thorsten Braun

  • Antonio Curti

  • Jordi Esteve

  • Carolyn Grove

  • Brian Andrew Jonas

  • Asim Khwaja

  • Ollivier Legrand

  • Pierre Peterlin

  • Olga Polyanskaya

  • Jennifer Sweeney

  • Hesham Mohamed

  • Jorge E. Cortes

  • Pierre Fenaux

Medical Centers

  • Institut Gustave-Roussy, Villejuif, France

  • Princess Margaret Cancer Center, Toronto, ON, Canada

  • IUCT-Oncopole, CHU de Toulouse,Toulouse,France

  • The Alfred Hospital and Monash University, Melbourne, Australia

  • Hospital Universitari I Politecnic La Fe, Valencia, Spain

  • The Royal Marsden Hospital, London, United Kingdom

  • CHU Bordeaux – Université de Bordeaux, France

  • Avicenne Hospital Paris XIII University,Bobigny,France

  • IRCCS Azienda Ospedaliero-Universitaria di Bologna,Bologna,Italy

  • Hospital Clinic Barcelona, Barcelona, Spain

  • Sir Charles Gairdner Hospital, Perth, Australia

  • University of California, Davis School of Medicine, Sacramento, CA

  • Kings College London, London, United Kingdom

  • Hopital Saint Antoine and Universite Pierre et Marie Curie, Paris, France

  • Nantes University Hospital, Nantes, France

  • FORMA Therapeutics, Inc., Watertown, MA

  • FORMA Therapeutics, Inc., Watertown, MA

  • Georgia Cancer Center, Augusta, GA, Service d’Hématologie Séniors, Hôpital Saint-Louis, Université Paris 7, Paris, France

Locations

  • France

  • Canada

  • Australia

  • Spain

  • United Kingdom

  • Italy

Companies

  • Forma Therapeutics,

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute myelocytic leukemia

Biomarkers

  • N/A

Drug/Treatment

  • FT-2102

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT02719574

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved